samedan logo
 
 
 
spacer
home > ebr > spring 2004 > the challenges in the development of hormonal preparations for women of a reproductive age
PUBLICATIONS
European Biopharmaceutical Review

the Challenges in the Development of Hormonal Preparations for Women of a Reproductive Age

The majority of women use hormonal preparations in the course of their lives, mainly for contraception. In the past, new drugs were tested in men only, due to the potential risks of foetal harm should a woman become pregnant. Yet nowadays it has become widely acceptable to develop preparations in young, healthy women, according to a guideline from the Food and Drug Administration (FDA, 1993). So with no restriction on the participation of women with childbearing potential in all phases of drug trials, we now see gender analysis which pays special attention to factors affecting pharmacokinetics, such as the role of the menstrual cycle and exogenous hormone therapy in relation to the drug, as well as the influence of the drug on oral contraceptives.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Doris Heger-Mahn, Medical Director and Executive, Astrid Breitschaft, Sub-Investigator and Marjo Ramakers, Research Physician at dinox Clinical Research

Doris Heger-Mahn has been a Medical Director and Executive at dinox since 1999. During the previous 10 years Doris held a number of positions at Schering AG, initially specialising in the assessment of female hormonal drugs, before moving into clinical development oncology and clinical operations. Her expertise lies in the development of drugs for female health. Doris completed her medical studies at the Free University Hospital in Berlin in 1986, and became a specialist in clinical pharmacology.


Astrid Breitschaft has been a Sub-Investigator at dinox since 2003. She began her career as a physician at the Robert-Rössle hospital, which is part of the University Hospital Charité in Berlin, participating in several oncology clinical trials. Astrid is currently working on her dissertation, which evaluates the influence of blood group constellations on the duration of transfusion dependency after ABO incompatible haematopoietic stem cell transplantation. She completed her medical studies at the Free University in Berlin in 1997.


Marjo Ramakers is a registered Sexologist, and has been conducting sexological clinical trials at dinox since 2002. In 1993 she founded a sexology outpatient clinic and for the next seven years worked at the Department of Sexology and Psychosomatic Gynaecology in the Academic Medical Center in Amsterdam, where she specialised in diagnosis and treatment of vulvodynia, dyspareunia and pelvic floor dysfunction. Marjo is currently writing a treatise on new outpatient clinic sexology.

spacer
Doris Heger-Mahn
spacer
spacer
spacer
Astrid Breitschaft
spacer
spacer
spacer
Marjo Ramakers
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Stevanato Group signs an agreement with Nelson Labs to provide best-in-class Extractables and Leachables testing services at its US Technology Excellence Center

Piombino Dese, Padua Italy and Salt Lake City, USA September 2, 2020: Italian-based Stevanato Group, a leading producer of glass primary packaging and provider of integrated services for combination products, and Nelson Laboratories, LLC, a global provider of lab testing and expert advisory services signed today a partnership agreement that will provide Extractables and Leachables testing at SG US Technology Excellence Center in Boston, MA.
More info >>

White Papers
 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement